Actively Recruiting

Phase 2
Phase 3
MALE
NCT04242017

Long-term Better Than Short-term ADT With Salvage RT

Led by Universitaire Ziekenhuizen KU Leuven · Updated on 2023-12-13

394

Participants Needed

3

Research Sites

551 weeks

Total Duration

On this page

Sponsors

U

Universitaire Ziekenhuizen KU Leuven

Lead Sponsor

I

Ipsen

Collaborating Sponsor

AI-Summary

What this Trial Is About

A randomized, multicenter, prospective PHASE II trial to assess the effect of short- versus long-term adjuvant ADT with high dose salvage radiotherapy on distant metastasis free survival in case of biochemical relapse (BR) after radical prostatectomy.

CONDITIONS

Official Title

Long-term Better Than Short-term ADT With Salvage RT

Who Can Participate

MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • History of confirmed prostate cancer treated with radical prostatectomy and extended pelvic lymph node dissection including removal of external iliac, internal iliac, and obturator nodes
  • Node-negative status (pN0) confirmed after surgery
  • Asymptomatic PSA rise post-prostatectomy of at least 0.2 µg/l confirmed twice, or from 0.15 µg/l for high-risk cases (Gleason 8-10, pT3b, or positive margins)
  • No additional staging required if PSA less than 0.4 ng/ml; mandatory PSMA PET-CT imaging if PSA above 0.4 ng/ml
  • Testosterone level above 150 ng/dl
  • ECOG performance status 0 or 1
  • Life expectancy longer than 5 years
  • Signed informed consent
Not Eligible

You will not qualify if you...

  • Presence of lymph node-positive disease (pN1) at surgery
  • Evidence of distant metastasis at referral (M1a-c), confirmed by PET-CT if PSA above 0.4 ng/ml
  • PSA below 0.2 ng/ml at referral
  • Prior radiotherapy preventing new radiotherapy due to overlapping fields
  • Known contraindications to radiation therapy (e.g., Ulcerative Colitis, Crohn Disease, Ataxia Teleangiectasia)
  • Current treatment with ADT or PSA-affecting drugs (e.g., finasteride, dutasteride, high-dose corticosteroids)
  • Inability to understand the treatment protocol or provide informed consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

AZ Maria Middelares

Ghent, Belgium

Actively Recruiting

2

UZ Gent

Ghent, Belgium

Actively Recruiting

3

UZ Leuven

Leuven, Belgium

Actively Recruiting

Loading map...

Research Team

C

Charlien Berghen, MD

CONTACT

G

Gert De Meerleer, MD, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here